Logo

Taiho Oncology's Futibatinib (TAS-120) Receives the US FDA's Breakthrough Therapy Designation for Advanced Cholangiocarcinoma

Share this
Taiho Oncology's Futibatinib (TAS-120) Receives the US FDA's Breakthrough Therapy Designation for Advanced Cholangiocarcinoma

Taiho Oncology's Futibatinib (TAS-120) Receives the US FDA's Breakthrough Therapy Designation for Advanced Cholangiocarcinoma

Shots:

  • The designation is based on efficacy & safety results from the P-II FOENIX-CCA2 study involves assessing futibatinib (TAS-120) in patients with advanced cholangiocarcinoma. The findings will be presented at AACR 2021
  • The preliminary clinical evidence showed improvement on at least one clinical EPs over available therapy
  • Futibatinib (TAS-120- PO) is a covalently-binding FGFR inhibitor for the treatment of patients with previously treated LA/m-cholangiocarcinoma harboring FGFR2 gene rearrangements- including gene fusions

  Ref: PRNewswire | Image: PRNewswire

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions